All In Biotech

Drug Trial Radar · NCT05655182

A Study of BLB-201 RSV Vaccine in Infants and Children

A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

137

Planned (sponsor's estimate)

Start

Mar 9, 2023

Primary completion

Dec 30, 2028

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Blue Lake Biotechnology Inc.Industry
Sponsor type
Industry
First posted
Dec 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 5 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • PIV5-vectored RSV Vaccine (BLB-201) Low DoseBiological

    BLB201 10\^6 PFU

  • PIV5-vectored RSV Vaccine (BLB-201) High DoseBiological

    BLB201 10\^7 PFU

  • PlaceboDrug

    The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Solicited Adverse EventsTime frame: Day 1-15
  2. Unsolicited Adverse EventsTime frame: Day 1-29

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Paradigm Clinical Research

    La Mesa, California · Recruiting

  • Paradigm Clinical Research - Modesto

    Modesto, California · Recruiting

  • University of California, San Diego

    San Diego, California · Recruiting

  • Paradigm Clinical Research Centers, LLC - Colorado, 1550 South Potomac Street, Suite 340

    Aurora, Colorado · Recruiting

  • Emory Children's Center- Vaccine Research Clinic

    Atlanta, Georgia · Recruiting

  • Velocity Clinical Research, Boise

    Meridian, Idaho · Completed

  • Clinical Research Prime

    Rexburg, Idaho · Recruiting

  • AMR Newton

    Newton, Kansas · Recruiting

  • Velocity Clinical Research - Lafayette

    Lafayette, Louisiana · Completed

  • Michigan Institute of Research

    Allen Park, Michigan · Recruiting

  • Velocity Clinical Research, Grand Island

    Grand Island, Nebraska · Recruiting

  • Be Well Clinical Studies

    Lincoln, Nebraska · Recruiting

  • Velocity Clinical Research, Cleveland

    Beachwood, Ohio · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Tribe Clinical Research, LLC Parkside Pediatrics Verdae

    Greenville, South Carolina · Recruiting

  • Tribe Clinical Research, LLC Parkside Pediatrics

    Greenville, South Carolina · Recruiting

  • Velocity Clinical Research, Austin

    Cedar Park, Texas · Active not recruiting

  • Baylor College of Medicine

    Houston, Texas · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.